IMPACT OF THE SOCIOECONOMIC STATUS ON THE PROBABILITY OF RECEIVING FORMULARY RESTRICTED THIAZOLIDINEDIONES (TZDS)

Main Article Content

Marc Dorais
Jacques LeLorier

Keywords

Restricted drugs, TZDs, diabetes

Abstract

Background


In the province of Quebec, Canada, the reimbursement of thiazolidinediones (TZDs) is limited to patients who do not respond to doses of metformin and a sulfonylurea.


 Objectives


The objective of this research project was to study, in a real-life setting, the “risk factors” for receiving these restricted drugs among patients who meet the reimbursement criteria.


 Methods


Among patients eligible for drug coverage under the RAMQ between May 2000 and June 2005, we selected those who received six consecutive dispensations of high doses of both metformin and a sulfonylurea. The date of the sixth dispensation was set as the index date. The proportion of patients who received a TZD in the year following the index date was calculated and a logistic regression was used to estimate the impact of several factors on the probability of receiving a TZD.


 Results


There were 4,836 patients in the cohort. A TZD was dispensed to 24.9% (95% CI: 23.7%;26.2%) of the patients. Compared to the oldest group of patients (65 years and more), the probability to receive a TZD was higher for patients aged 51 to 64 years (OR=1.33 95% CI: 1.11;1.59) and patients aged 19 to 50 years [OR=1.81 (95% CI: 1.40;2.33)]. Patients with the highest income were more likely to receive a TZD (OR=1.55 95% CI: 1.21;1.98) compared to patients with the lowest income.


 Conclusions


These findings suggest that the restricted access to TZDs probably results in social inequities, as individuals with lower incomes are less likely to receive these drugs.

Abstract 105 | PDF Downloads 47

References

1. Régie de l'assurance maladie du Québec. Liste de médicaments. http://www.ramq.gouv.qc.ca/fr/professionnels/liste med/pdf/modification/liste_medicaments.zip Accessed November 22, 2006.
2. Yki- Jarvinen H. Drug therapy: Thiazolidinediones.New England Journal of Medicine 2004; 351(11):1106-1118.
3. Cheng AY, Fantus IG. Thiazolidinedione- induced congestive heart failure. Annals of Pharmacotherapy 2004;38(5):817-820.
4. Vo nkorff M, Wagner EH, Saunders K. A Chronic Disease Score from Automated Pharmacy Data. Journal of Clinical Epidemiology 1992;45(2):197-203.
5. Tamblyn R, Lavoie G, Petrella L, Monette J. The Use of Prescription Claims Databases in Pharmacoepidemiologic Research - the Accuracy and Comprehensiveness of the Prescription Claims Database in Quebec. Journal of Clinical Epidemiology 1995;48(8):999-1009.
6. Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997;350:979-982.
7. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid- lowering medications. JAMA 1998; 279(18):1458-1462.
8. Rahme E, LeLorier J. Gastrointestinal health care r esource use and costs associated with nonsteroidal anti- inflammatory drugs versus acetaminophen. Arthritis & Rheumatism 2000;43[4]:917- 921.

Most read articles by the same author(s)